The lung cancer exercise training study: a randomized trial of aerobic training, resistance training, or both in postsurgical lung cancer patients: rationale and design.
BACKGROUND
The Lung Cancer Exercise Training Study (LUNGEVITY) is a randomized trial to investigate the efficacy of different types of exercise training on cardiorespiratory fitness (VO2peak), patient-reported outcomes, and the organ components that govern VO2peak in post-operative non-small cell lung cancer (NSCLC) patients.


METHODS
Using a single-center, randomized design, 160 subjects (40 patients/study arm) with histologically confirmed stage I-IIIA NSCLC following curative-intent complete surgical resection at Duke University Medical Center (DUMC) will be potentially eligible for this trial. Following baseline assessments, eligible participants will be randomly assigned to one of four conditions: (1) aerobic training alone, (2) resistance training alone, (3) the combination of aerobic and resistance training, or (4) attention-control (progressive stretching). The ultimate goal for all exercise training groups will be 3 supervised exercise sessions per week an intensity above 70% of the individually determined VO2peak for aerobic training and an intensity between 60 and 80% of one-repetition maximum for resistance training, for 30-45 minutes/session. Progressive stretching will be matched to the exercise groups in terms of program length (i.e., 16 weeks), social interaction (participants will receive one-on-one instruction), and duration (30-45 mins/session). The primary study endpoint is VO2peak. Secondary endpoints include: patient-reported outcomes (PROs) (e.g., quality of life, fatigue, depression, etc.) and organ components of the oxygen cascade (i.e., pulmonary function, cardiac function, skeletal muscle function). All endpoints will be assessed at baseline and postintervention (16 weeks). Substudies will include genetic studies regarding individual responses to an exercise stimulus, theoretical determinants of exercise adherence, examination of the psychological mediators of the exercise - PRO relationship, and exercise-induced changes in gene expression.


CONCLUSIONS
VO2peak is becoming increasingly recognized as an outcome of major importance in NSCLC. LUNGEVITY will identify the optimal form of exercise training for NSCLC survivors as well as provide insight into the physiological mechanisms underlying this effect. Overall, this study will contribute to the establishment of clinical exercise therapy rehabilitation guidelines for patients across the entire NSCLC continuum.


BACKGROUND
NCT00018255.
Jones
Lee W
LW
Duke University Medical Center, Durham, NC, USA. jones442@mc.duke.edu
Eves
Neil D
ND
Kraus
William E
WE
Potti
Anil
A
Crawford
Jeffrey
J
Blumenthal
James A
JA
Peterson
Bercedis L
BL
Douglas
Pamela S
PS
D000328:Adult; D000332:Aerobiosis; D002289:Carcinoma, Non-Small-Cell Lung / Q000503:physiopathology / Q000534:rehabilitation / Q000601:surgery / Q000628:therapy*; D023381:Endpoint Determination; D015444:Exercise / Q000502:physiology; D005081:Exercise Therapy / Q000379:methods*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000503:physiopathology / Q000534:rehabilitation / Q000601:surgery / Q000628:therapy*; D008297:Male; D010101:Oxygen Consumption / Q000502:physiology; D010349:Patient Compliance; D055070:Resistance Training / Q000379:methods
Cancer. 2007 Dec 1;110(11):2511-8
17955504
J Appl Physiol (1985). 2008 Apr;104(4):1069-79
18258800
J Clin Oncol. 2008 Feb 20;26(6):907-12
18281663
Respir Med. 2007 Nov;101(11):2336-42
17686622
Methods Mol Biol. 2009;472:169-89
19107433
Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):87-95
19124485
J Clin Oncol. 2007 Jun 10;25(17):2345-51
17557947
Am J Physiol Heart Circ Physiol. 2004 Apr;286(4):H1565-72
14684375
Circulation. 2000 Feb 22;101(7):828-33
10683360
Respirology. 2006 Nov;11(6):681-6
17052294
Thorax. 2006 Jan;61(1):57-60
16244091
J Clin Oncol. 2007 Jun 10;25(17):2335-7
17557943
Can J Cardiol. 2005 Dec;21(14):1277-80
16341296
Breast J. 2009 Jan-Feb;15(1):45-51
19120381
J Am Coll Cardiol. 2002 Apr 3;39(7):1170-4
11923042
Cancer. 2007 Aug 1;110(3):590-8
17582629
Ann Intern Med. 2008 Feb 19;148(4):295-309
18283207
Br J Cancer. 2000 Feb;82(4):800-5
10732749
Am J Surg. 2006 Nov;192(5):565-71
17071185
Oncol Nurs Forum. 2006 Sep 01;33(5):937-47; quiz 948-50
16955122
Psychooncology. 2009 Feb;18(2):128-33
18536022
J Clin Oncol. 2008 Aug 20;26(24):3958-64
18711185
CMAJ. 1999 May 4;160(9 Suppl):S29-34
10333851
Am J Phys Med Rehabil. 2002 Nov;81(11 Suppl):S3-16
12409807
Ann Surg Oncol. 2009 Jan;16(1):106-12
18953612
Chest. 2003 Jan;123(1 Suppl):105S-114S
12527570
J Clin Oncol. 2005 Feb 1;23(4):899-909
15681536
J Cancer Surviv. 2007 Jun;1(2):116-28
18648952
J Appl Physiol (1985). 1994 Aug;77(2):998-1005
8002557
Circulation. 1979 Sep;60(3):547-55
455617
J Gerontol A Biol Sci Med Sci. 2000 Jul;55(7):B336-46
10898247
J Clin Oncol. 2008 Jan 10;26(2):233-41
18086802
Eur J Appl Physiol. 2002 Nov;88(1-2):50-60
12436270
Cancer. 2008 Dec 15;113(12):3430-9
18988290
N Engl J Med. 2002 Mar 14;346(11):793-801
11893790
Chest. 2003 Jan;123(1 Suppl):97S-104S
12527569
Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):379-86
18250341
Lancet Oncol. 2006 Dec;7(12):1017-26
17138223
Pflugers Arch. 1997 Jan;433(3):238-44
9064638
Prog Cardiovasc Nurs. 2001 Fall;16(4):142-51
11684905
JAMA. 2005 May 25;293(20):2479-86
15914748
Curr Oncol. 2007 Oct;14(5):173-9
17938700
Clin Breast Cancer. 2008 Feb;8(1):70-9
18501061
Am J Epidemiol. 1988 Dec;128(6):1340-51
3264110
Lung Cancer. 1995 Jun;12(3):199-220
7655830
Lung Cancer. 2007 Feb;55(2):225-32
17113185
Lancet Oncol. 2008 Aug;9(8):757-65
18672211
J Appl Physiol (1985). 1997 Apr;82(4):1305-10
9104869
Thorac Surg Clin. 2004 Aug;14(3):353-65
15382767
Curr Oncol Rep. 2009 Jul;11(4):255-62
19508829
Annu Rev Psychol. 2001;52:27-58
11148298
Lung Cancer. 2007 Aug;57(2):175-80
17442449
Med Sci Sports Exerc. 1998 Jun;30(6):975-91
9624661
Clin Cardiol. 1979 Aug;2(4):257-63
262574
Lancet Oncol. 2009 Jun;10(6):598-605
19482248
Circulation. 2002 Aug 6;106(6):666-71
12163425
J Pain Symptom Manage. 2005 Aug;30(2):160-9
16125031
Respir Physiol. 1991 Jan;83(1):11-21
2028103
Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):306-13
19124513
CMAJ. 2006 Jul 4;175(1):34-41
16818906
Semin Hematol. 1997 Jul;34(3 Suppl 2):13-9
9253779
J Clin Invest. 1965 Sep;44:1514-22
14332164
Chest. 1993 Jul;104(1):155-9
8325061
BMJ. 1999 Apr 3;318(7188):901-4
10102851